Feb 02, 2021 / 09:30PM GMT
Operator
Greetings, and welcome to the DURECT Corporation conference call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Mike Arenberg, Chief Financial Officer. Please go ahead.
Michael H. Arenberg - DURECT Corporation - CFO & Secretary
Good afternoon, and welcome to our conference call to discuss the POSIMIR approval. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation.
Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding POSIMIR as well as DURECT's products in development, expected product benefits, regulatory and partnering strategies, our development plans, future clinical trials or projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings,
DURECT Corporation - Special Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers